RB1 and bladder transitional cell carcinoma: Genomic characterization of PDOs derived from Patient 2 showed that both samples harbored a mutation in the CDKN1A gene (Q29*), a target frequently mutated in BLCa and associated with tumor progression24, and in RB1 gene (S624C, Fig. 6g).